Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Renganayaki Pandurengan"'
Autor:
Manouchehr Hessabi, Mohammad H. Rahbar, Andrew D Barreto, Amber Jacobs, James C. Grotta, Hari Indupuru, Melvin R Sline, Gary A. Ford, Aisha S. Dickerson, Loren Shen, Claudia Pedroza, Chunyan Cai, Rigoberto I Delgado, Renganayaki Pandurengan, Claire MacDonald
Publikováno v:
Contemporary Clinical Trials. 44:139-148
Background We describe innovations in the study design and the efficient data coordination of a randomized multicenter trial of Argatroban in Combination with Recombinant Tissue Plasminogen Activator for Acute Stroke (ARTSS-2). Methods ARTSS-2 is a 3
Autor:
Claire MacDonald, Renganayaki Pandurengan, Navdeep Sangha, James C. Grotta, Amber Jacobs, Andrei V. Alexandrov, Mohammad H. Rahbar, Gary A. Ford, Christine Roffe, Steven R. Levine, Zahra G Ajani, Bart Piechowski, Michael T. Mullen, Andrew D Barreto, Loren F Shen
Publikováno v:
Stroke. 46
Background: Enrollment into acute ischemic stroke (AIS) trials is usually limited to weekday working hours. At our center, the majority of patients (64%) that receive tPA arrive after-hours. As a result, a large portion of eligible patients do not re
Autor:
Tzu-Ching Wu, James C. Grotta, Mohammad H. Rahbar, Andrew D Barreto, Chunyan Cai, Digvijaya Navalkele, Nicole R. Gonzales, Amrou Sarraj, Renganayaki Pandurengan
Publikováno v:
Stroke. 46
Background: Per American Heart Association guidelines, blood pressure (BP) should be < 185/110 to be eligible for intravenous tissue plasminogen activator (tPA). It is shown that door to needle (DTN) time is prolonged in patients who require anti-hyp
Autor:
Andrei V. Alexandrov, Kristian Barlinn, Rebecca M. Sugg, Sheryl Martin-Schild, Zsolt Garami, P. Lyden, Clotilde Balucani, Andrew M. Demchuk, James C. Grotta, Sean I Savitz, Renganayaki Pandurengan, Zhongxue Chen, Robert Mikulik, Nicole R. Gonzales, Jessica Lee, Loren Shen, April Sisson, Tzu C Wu, Andrew D Barreto, Mohammad H. Rahbar, Georgios Tsivgoulis
Publikováno v:
Stroke. 43(3)
Background and Purpose— Argatroban is a direct thrombin inhibitor that safely augments recanalization achieved by tissue-type plasminogen activator (tPA) in animal stroke models. The Argatroban tPA Stroke Study was an open-label, pilot safety study
Autor:
Federica Macellari, Simone Beretta, Mauro Silvestrini, Andrew M. Demchuk, Michele Venti, Danilo Toni, Charlotte Cordonnier, Mascia Nesi, Claudia Trentini, Giovanni Orlandi, Paolo Bovi, Renganayaki Pandurengan, Alessia Lanari, Andrea Alberti, Ioannis Heliopoulos, Rossana Tassi, Simona Marcheselli, Frédéric Dumont, Antonio Baldi, Alessandro Padovani, Serena Monaco, Charitomeni Piperidou, Giuseppe Martini, James C. Grotta, Didier Leys, Elisabetta Traverso, Carlo Ferrarese, Edoardo Donati, Maurizio Paciaroni, Alessandro Pezzini, Valeria Caso, Emilio Luda, Sung Il Sohn, Giorgio Silvestrelli, Francesco Corea, Clotilde Balucani, Simerpreet Bal, Patrizia Nencini, Jessica Kepplinger, Manuel Cappellari, Farhaan S Vahidy, Monica Acciarresi, Cataldo D'Amore, Stéphanie Debette, Andrei V. Alexandrov, Ulf Bodechtel, Nicole R. Gonzales, Melvin R Sline, Paolo Previdi, Sebastiano D'Anna, Domenico Consoli, Domenico Inzitari, Gino Gialdini, Maria Luisa DeLodovici, Alberto Chiti, Massimo Del Sette, Giampiero Galletti, Giancarlo Agnelli, Paolo Invernizzi, Giorgio Bono, Georgios Tsivgoulis, Kristian Barlinn, Raffaella Cerqua, Luisa Fofi
Background and Purpose— The beneficial effect of intravenous thrombolytic therapy in patients with acute ischemic stroke attributable to internal carotid artery (ICA) occlusion remains unclear. The aim of this study was to evaluate the efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1df752c79f692722960e750e2fcdf0c3
http://hdl.handle.net/11365/974720
http://hdl.handle.net/11365/974720